Bausch & Lomb (TSX:BLCO) Construction In Progress : C$466 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Construction In Progress?

Bausch & Lomb's quarterly construction in progress stayed the same from Jun. 2023 (C$0 Mil) to Sep. 2023 (C$0 Mil) but then increased from Sep. 2023 (C$0 Mil) to Dec. 2023 (C$466 Mil).

Bausch & Lomb's annual construction in progress declined from Dec. 2021 (C$675 Mil) to Dec. 2022 (C$322 Mil) but then increased from Dec. 2022 (C$322 Mil) to Dec. 2023 (C$466 Mil).

Bausch & Lomb Construction In Progress Historical Data

The historical data trend for Bausch & Lomb's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Construction In Progress Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

279.18

507.24

674.56

321.96

465.54

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Construction In Progress	Get a 7-Day Free Trial											321.96	-	-	-	465.54

Bausch & Lomb Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.